RecruitingNCT06868355

APACE - Feasibility of Using Accelerometers to Measure Physical Activity in Cancer Patients on Early Phase Clinical Trials

APACE - Feasibility of Using Accelerometers to Measure Physical Activity in Cancer Patients on Early Phase Clinical Trials. A Feasibility Study Evaluating the Use of Accelerometers to Capture Physical Activity Levels in Cancer Patients on Early Phase Clinical Trials


Sponsor

University of Manchester

Enrollment

40 participants

Start Date

Sep 28, 2023

Study Type

OBSERVATIONAL

Conditions

Summary

Increased physical activity has been shown to improve outcomes for cancer patients, however the measure of activity is highly variable and understudied in cancer patients on early phase clinical trials where activity is used as a criteria for eligibility. Additionally, more than half of cancer patients experience fatigue at some point in their treatment with exercise and psychosocial interventions currently recommended as interventions. Therefore, it is important to be able to more accurately measure activity and fatigue in cancer patients to ensure adequate intervention, management and appropriate access to treatment. This proposal is a non-interventional feasibility study designed to collect activity and sleep data from patients with advanced cancer newly enrolled in early phase clinical trials. The data will be collected over a 5-6 week period using a wearable accelerometer device. This study will be conducted concurrently with the early phase trial related activities/treatment and will have no impact on a patient's clinical pathway. Data generated from the study will be used to evaluate the feasibility of collecting activity and sleep data from patients with advanced cancer on early phase clinical trials. In this study, participants in the UK will be able to opt-in to using eNutri, a web-based graphical food frequency questionnaire (FFQ), and provide feedback on its usability. The output of eNUTRI will help us understand if there is a use for eNutri in cancer care environments for a range of purposes such as providing nutritional support for cancer patients, and exploring drug-nutrient interactions on the patient outcome.


Eligibility

Min Age: 16 Years

Inclusion Criteria6

  • Voluntary informed consent.
  • Aged at least 16 years.
  • Consented to an early phase clinical trial.
  • Willingness to wear a device for the duration of the study.
  • Willingness to comply with scheduled study procedures.
  • ECOG PS 0 or 1.

Exclusion Criteria2

  • Judgement by the investigator that the individual should not participate if they are unlikely to comply with study procedures and requirements.
  • Patient deemed ineligible for enrolment onto an early phase clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERNo intervention (observational study)

This is an observational study


Locations(8)

National Cancer Institute of Milan (INT)

Milan, Italy

Vall d'Hebron Institute of Oncology (VHIO)

Barcelona, Spain

START Madrid CIOCC

Madrid, Spain

START Madrid Fundación Jiménez Díaz (FJD) Quiron Salud Hospital

Madrid, Spain

Clínica Universidad de Navarra

Pamplona, Spain

Instituto de Investigación Sanitaria (INCLIVA)

Valencia, Spain

University Hospitals of Leicester NHS Trust

Leicester, United Kingdom

The Christie NHS Foundation Trust

Manchester, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06868355


Related Trials